温州小姐-温州小姐_主页

在临沧酒店晚上怎么叫服务

Welcome to the official website of Yantai Dongcheng Pharmaceutical Group Co., Ltd!
Stock Code: 002675
Chengdu Yunke Pharmaceutical Co., Ltd
Your current position: home page >> subsidiary >>Chengdu Yunke Pharmaceutical Co., Ltd

Chengdu Yunke Pharmaceutical Co., Ltd., formerly known as Chengdu Institute of isotope application of China Nuclear Power Research and Design Institute (founded in 1992), was restructured and established in July 2001. The company is located in Chengdu high tech Development Zone, a national high-tech development zone. The factory area is located in Southwest Airport Economic Development Zone. It is a cultivation enterprise of innovative enterprises in Sichuan Province and a national high-tech enterprise.   

The company has established a standard plant of more than 6000 square meters in Chengdu National High Tech Development Zone, and has become the first enterprise in the field of nuclide medicine to pass GMP certification. There are specialized research and experimental bases such as drug development and Research Institute, biological research laboratory, quality control laboratory, relevant Isotope Laboratory, and drug clinical observation and treatment center. The enterprise is specialized in technical research of radioactive drugs, product development, production and sales, technical consultation and technical service. There are specialized drug development institutions, chemical and biological research laboratories, quality control laboratories, radiochemistry laboratories, clinical observation and treatment centers, GMP standard workshops and sales network all over the country.

At present, the company is in a leading position in the domestic supply of radionuclide therapy drugs. As a high-tech enterprise, the company has been adhering to the development concept of "based on radionuclide and growing together with the cause of radionuclide therapy in China". It is committed to the development and production of radionuclide drugs, and has been widely concerned and supported by medical circles and drug research institutions. The company has a complete R & D team from researcher to intern researcher system and efficient marketing system covering the whole country. The company has researchers, senior engineers, pharmacists, doctors and other full-scale scientific research personnel, accounting for 85% of the company's personnel. They have made great achievements in the research, development, production, clinical application, marketing and other aspects of new drugs. With its unique talent, technology and product advantages, the company has expanded the market scale of its products and has initially formed a nationwide sales network.

 

 

The company is a doctoral training center of "nuclear technology and application" of China Nuclear Power Research and Design Institute, with 3 doctoral supervisors and 6 Master tutors. The company's technical personnel include members of the State Pharmacopoeia Committee, national drug evaluation experts, National Natural Science Foundation project evaluation experts, National 863 Program project review experts, and members of the national nuclear energy Standardization Technical Committee. It has technical and human resources reserve in radionuclide research, monoclonal antibody research, radiopharmaceutical development, including radionuclide labeled monoclonal antibody drug research. The company has successfully developed nine radioimmunoassay kits and in vivo imaging diagnostic kits, and technetium [99Tc] methylene diphosphonate injection (trade name: "Yunke") for the treatment of rheumatoid arthritis and bone diseases. Among them, "Yunke" is one of the radionuclide drugs with independent intellectual property rights in China, and has obtained the national invention patent (zl94113006.1) and the certificate of "national key new products" Many experiments and clinical verification show that Yunke can regulate the immune function of human body, repair the damaged cartilage tissue, reverse the pathological changes, and then restore the function of bone and joint. It breaks the difficulty in the treatment of rheumatoid arthritis and makes a new interpretation for the ideal drug for the treatment of rheumatoid arthritis. The company has successively won 4 national invention patents, 1 Chinese patent Excellence Award, and 1 ministerial second prize for scientific and technological progress. At present, 7 invention patent applications are under trial.

 

 

In the future, based on nuclear technology, the company will further expand the production capacity and variety range of existing products, develop characteristic and independent intellectual property drugs with good prospects, and contribute to the cause of nuclear medicine in China. At the same time, we are looking for cooperation to push our superior products to overseas markets. Based on the development of market scale, the company will further improve its internal management, expand its scale, use first-class R & D and production equipment, and complete and standardized quality management system, so that the company will be in line with international pharmaceutical enterprises and become a modern nuclear diagnosis and treatment industry and research service enterprise with unique advantages in China.

 

contact us CONTACT US
0535-6391521
Switchboard: 86-535-6391521 / 6391522
Email: zxu @ midatlanticlegends.com
Address: No.7 Changbaishan Road, Yantai Development Zone, Shandong Province
Copyright 2014 Yantai Dongcheng Pharmaceutical Group Co., Ltd. All Rights Reserved Lu ICP Bei 18035060-1